Xu Wencheng, Meng Kehan, Wu Hongguang, Miura Taro, Suzuki Shunsuke, Chiyotanda Masako, Tanaka Sachiko, Sugiyama Kentaro, Kawashima Hisashi, Hirano Toshihiko
Department of Pharmacy, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
Institute of Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
Pediatr Int. 2019 Dec;61(12):1188-1195. doi: 10.1111/ped.14014. Epub 2019 Dec 13.
Over 20 kinds of steroids, tacrolimus ointments, and cyclosporine capsules are usually recommended for the treatment of atopic dermatitis (AD), depending on the symptoms of patients. However, several side effects sometimes occur with the extensive use of these agents for the treatment of pediatric AD patients. The purpose of this study was to explore whether vitamin K could be a new immunosuppressive candidate for pediatric patients with AD.
The immunosuppressive efficacy of vitamin K was evaluated through a cell-culture procedure using mitogen-activated peripheral blood mononuclear cells (PBMCs) obtained from pediatric AD patients.
The mean (SD) IC value of vitamin K for the proliferation of concanavalin A-activated PBMCs was 15.37 (30.05) μmol/L, while the value for tacrolimus was 0.10 (0.28) ng/mL (0.12 (0.35) nmol/L). There was a significant correlation between the IC values for vitamin K and those for tacrolimus (P = 0.0001, r = 0.8871). However, there was no significant correlation between the IC values of vitamin K and those of cyclosporine A or methylprednisolone. A significant correlation between the IC values of vitamin K or tacrolimus and blood eosinophil counts (P = 0.0099, r = 0.7086 and P = 0.0032, r = 0.7722, respectively) was observed.
Vitamin K -inhibited T-cell mitogen stimulated proliferation of PBMCs from pediatric AD patients in a dose-dependent manner. The PBMCs from pediatric AD patients were more sensitive to the immunosuppressive efficacy of vitamin K than the PBMCs from healthy subjects. The individual immunosuppressive pharmacological efficacy of vitamin K and of tacrolimus could be inferred from the blood eosinophil count of pediatric AD patients.
根据患者症状，通常推荐使用20多种类固醇、他克莫司软膏和环孢素胶囊来治疗特应性皮炎（AD）。然而，在广泛使用这些药物治疗小儿AD患者时，有时会出现一些副作用。本研究的目的是探讨维生素K是否可能成为小儿AD患者的一种新的免疫抑制候选药物。
通过细胞培养程序，使用从小儿AD患者获得的丝裂原激活外周血单个核细胞（PBMC）评估维生素K的免疫抑制效果。
维生素K对刀豆球蛋白A激活的PBMC增殖的平均（标准差）IC值为15.37（30.05）μmol/L，而他克莫司的值为0.10（0.28）ng/mL（0.12（0.35）nmol/L）。维生素K和他克莫司的IC值之间存在显著相关性（P = 0.0001，r = 0.8871）。然而，维生素K与环孢素A或甲泼尼龙的IC值之间没有显著相关性。观察到维生素K或他克莫司的IC值与血嗜酸性粒细胞计数之间存在显著相关性（分别为P = 0.
